OncoMatch/Clinical Trials/NCT03829553
Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment
Is NCT03829553 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for breast cancer.
The main objective of this trial is to investigate the efficacy and safety of hypofractionated radiotherapy of 3 or 4 weeks by comparing with conventional radiotherapy of 5 or 6 weeks using intensity-modulated radiation therapy (IMRT) in breast cancer patients with an indication for regional nodal irradiation (RNI) following mastectomy or breast conserving surgery. Patients will be randomized to hypofractionated radiotherapy or conventional radiotherapy delivered to chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes). Eligible breast cancer patients will be followed for at least 5 years to evaluate the difference in 5-year locoregional recurrence, over survival, distant metastasis, toxicity and life quality between two groups.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Allowed: ESR1 expression testing allowed
Estrogen-receptor...can be performed on the primary breast tumor or axillary nodes.
Allowed: PR (PGR) expression testing allowed
Progesterone-receptor...can be performed on the primary breast tumor or axillary nodes.
Allowed: HER2 (ERBB2) expression testing allowed
human epidermal growth factor receptor-2 (HER-2)...can be performed on the primary breast tumor or axillary nodes.
Allowed: MKI67 expression testing allowed
Ki67 index can be performed on the primary breast tumor or axillary nodes.
Disease stage
Required: Stage PT1, PT2, PT3
pT1-3; Evidence of distant metastatic disease and/or T4 disease [excluded]
Prior therapy
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify